

# Pushing the Edge... With All Deliberate Speed

Joe Fredette
Senior Marketing & Business Development Manager
Biopharmaceuticals Business

©2018 Waters Corporation

### **Presentation Outline**



- Biopharma Industry Perspective
- How Waters is Responding
- Our Goal of Harmonization

Conference Highlights




A Race for Productivity is Underway!





# **Pharma Industry Forecast - 2020**



# Background – Major Industry Trends






Biosimilars fueling a race for greater productivity



Increased outsourcing



Larger and more complex molecules



Evolving Regulatory Requirements / Drive for Harmonization

©2018 Waters Corporation

# Current Efforts at Improving Productivity

Single-Use / Disposable Manufacturing

Quality by Design (QbD)

Continuous Manufacturing (CM)

# **Pharma Catches on to Continuous Manufacturing**

By Stephanie Neil, Automation World - December 6, 2017 Support from the FDA, industry groups and automation suppliers is helping pharmaceutical companies break the batch habit in favor of a continuous approach to drug production.



©2018 Waters Corporation

# Where Time is Lost Today





- Managing the hidden complexities and risks when transferring data & methods
- Ensuring data integrity and regulatory compliance across the organization
  - 2017 saw a doubling in the number of warning letters issued to drug product manufacturing sites\*
- System validation, maintenance and record keeping for GLP / GMP compliance
- Troubleshooting inconsistent analytical performance



# How is Waters Responding?


©2018 Waters Corporation

# **Our Vision**



A comprehensive portfolio of fit-for-purpose analytical tools that all work together within a single compliance-ready informatics environment; one that facilitates method and data transfers while preserving data integrity, and that creates workflow efficiencies that fuel productivity gains across the drug discovery, development and manufacturing pipeline






# **Dimensions of Innovation**



# **The Cutting Edge**

Pushing the edge of capability and performance





Focused on ruggedness, ease-of-use, size and affordability





Accessibility

# **Fit-for-Purpose Deployment of Mass Spectrometry**





Non-Regulated

**Regulated - GXP** 

## **Discovery & Characterization**

**Product & Process Monitoring / QC** 



Synapt G2 Si & VION HDMS



Xevo G2 XS

## "Mass Spectrometry"

- Most capable instruments
- Leading edge performance
- Expert level end users
- Large and not inexpensive



ACQUITY QDa

Future Offerings

### "Mass Detection"

- Designed for max. accessibility
  - •Ease-of use
  - Minimal training
  - Compact size
  - Affordable and Scalable
- •Rugged, Robust Performance

©2018 Waters Corporation

# **QDa Biopharma Applications**





Peptide-based

Multi-Attribute-Monitoring


Confirm product identity (ID)

- Peptide Map / Profile
- CDR peptides


Post Translational Modifications (PTM) analysis

- Oxidation
- Deamidation, et.al.
- Glycopeptide Analysis

Sequence variants, ...more



Synthetic Peptides




Released N-Glycans



Oligonucleotides



ADC Free Drug Analysis



Polysorbate 80 / 20 Stability Monitoring

© 2018 Waters Corporation 11




# So What Does a High Resolution Mass Detector Look Like?


# Fit for purpose attribute analysis for the most complex biotherapeutics

Visit Henry Shion at **Poster WP699** for more details












# Native SEC-MS of ADC Raw spectrum











# ASMS 2018: 66th Conference on Mass Spectrometry and Allied Topics Waters Biopharmaceutical Activities



# A Busy ASMS for the Waters Biopharm Team



#### Biopharmaceutical Presentations at ASMS 2018

#### BREAKFAST SEMINARS

7:00 am - 8:00 am

Waters Hospitality Suite, Hilton San Diego Bayfront

Space is limited. Register today at ⊳ www.waters.com/asms

#### Tuesday, June 5, 2018

The Benefits of Native Mass Spectrometry in Biotherapeutic Characterization

 Collision Induced Unfolding: A New Paradigm in Protein Stability Measurements

Presenter: Brandon T. Ruotolo, Ph.D, University of Michigan

 Hyphenation of Non-Denaturing Chromatographic Methods to Native Mass Spectrometry and Ion Mobility for Therapeutic Protein Characterization

Presenter: Mr. Anthony Ehkirch, University of Strasbourg

#### Wednesday, June 6, 2018

Get Automated: Achieve Your Automation Potential for Complex Large Molecule LC-MS Workflows Presenter: Jennifer Fournier, Director of Product Marketing, Chemistry Group, Waters Corporation

#### ORAL PRESENTATIONS

#### Monday, June 4, 2018, 9:50 am

Streamlining the Identification and Monitoring of Product and Process Attributes in Biopharmaceutical Development and QC with MAM-Based Workflows

Presenter: Weibin Chen, Waters Corporation

#### POSTER PRESENTATIONS

#### Monday, June 4, 2018

MP 300 LC-MS Glycan Analysis of Fusion Proteins
Facilitated by Rapid Glycosylamine Labeling
and Site-Specific Profiling

MP 430 Synthetic Peptide Impurity Analysis and Purification
MP 725 Significant Improvements in Spectral Quality
of Non-Covalent Protein Complexes using SEC-

#### Wednesday, June 6, 2018

Native MS

WP 042 Data Independent Acquisition Modes for Identification, Quantification and Monitoring of Low-Abundance Host Cell Proteins During Monoclonal Antibody Bioprocessing

WP 058 Analytical Scale Native SEC-MS for Robust Biotherapeutic Characterization

WP 171 Characterising the Catabolism of Peptides Using Ion Mobility Enabled High Resolution Mass Spectrometry

WP 676 Monitoring Critical Quality Attributes (CQA):
Core-Fucosylation of N-Glycans Using an Integrated Subunit LC-MS Workflow Method

WP 699 Towards Overcoming the Challenges of Implementing Accurate Mass MS for Routine Biotherapeutic Analysis

#### Thursday, June 7, 2018

ThP 5583 Bridging the Analytical Workflows for Characterizing and Monitoring Product Quality Attributes (PQAs) of Biotherapeutics by a Common Data Acquisition Mode

ThP 683 Optimizing Data Processing Parameters for HRMS-based Intact Level mAb Quantification

- 2 Breakfast Seminars on
  - Native MS
  - Sample Prep Automation (Digestion and Glycans)
- Oral on Multiple Attribute Monitoring (MAM)
- 10 Posters
  - Released Glycan and Glycopeptide Analysis
  - Multiple Attribute Monitoring (MAM)
  - Native MS and Native SEC-MS
  - Synthetic Peptide Impurity and Catabolism
  - Host Cell Protein Analysis
  - DIA Peptide Mapping
  - Intact Protein LCMS Quan

# Biopharmaceutical Breakfast Seminar





# BENEFITS OF NATIVE MASS SPECTROMETRY FOR BIOTHERAPEUTIC CHARACTERIZATION

Tue June 5<sup>th</sup>, 2018 7:00 – 8:00 AM Waters Suite- Hilton San Diego Bayfront

- Collision Induced Unfolding: A New Paradigm in Protein Stability Measurements. Brandon T. Ruotolo, Ph.D, Univ. of Michigan
- Hyphenation of Chromatographic Methods to Native Mass Spectrometry and Ion Mobility for Therapeutic Protein Characterization. Mr. Anthony Ehkirch, Univ. of Strasbourg
- Register at information desk or online at: www.waters.com/NativeMSbreakfast

Limited Spaces Remaining !!

## Waters Scientific Posters on SEC-Native MS



MP 725 - Improvement in Spectral Quality of Non-Covalent Protein Complexes using SEC-Native MS




Figure 3: Improvement of spectral quality for tetrameric ADH (147kD) using SEC-Native MS over static nanospray

WP 058 - Analytical Scale Native SEC-MS for Robust Biotherapeutic Characterization





Figure 5: SEC-Native MS of Trastuzumab-DM1 ADC. Deglycosylation was not required for this DAR analysis.

# Sample Preparation is no longer one dimensional for Released N-Glycan Analysis with GlycoWorks RapiFluor-MS





Low throughput Semi-Automation 8-24 samples

Higher throughput Automation 48-96 samples

- Platform scalability for 8 to 96 samples at a time
- Purposefully designed kits for manual use and automated liquid handling platforms
- Available base scripts and layouts for simplified deployment on larger bed liquid handling platforms.

### **Automation Breakfast Seminar**





GET AUTOMATED: ACHIEVE YOUR AUTOMATION POTENTIAL FOR COMPLEX LARGE MOLECULE LC-MS WORKFLOWS

Wed June 6<sup>th</sup>, 2018 7:00 – 8:00 AM Waters Suite- Hilton San Diego Bayfront

- Automation starts well before the robot. To obtain the benefits of automation your consumables need to be designed for automation platforms.
- Come see just how Waters is achieving this with the LC-MS workflows for protein quantification and released N-glycan analysis.
- Automation vendors, Andrew Alliance and Hamilton, are showcased in the Waters hospitality suite. Representatives will be there to answer questions.
- Presenter: Jennifer Fournier, Director of Product Marketing, Chemistry Group, Waters Corporation
- Register at information desk online at: www.waters.com/AutomationBreakfast

Limited Spaces Remaining !!

# Oral Presentation MOC am 9:50 on Multi-Attribute Monitoring Analysis for Process Dev and QC



Streamlining Identification and Monitoring of Critical Quality Attributes in Biopharmaceutical Development and QC Robert Birdsall, Ximo Zhang, Weibin Chen, and Ying Qing Yu

AS-FTN - Sample temp 10 °C

#### Binary Pump

- Mixer volume = 380 uL

- MP A =  $H_2O$ , 0.1% FA

- MP B = MeCN, 0.1% FA



#### CM-A (column heater)

- Column temp 60 °C
- Column CSH 2.1 x 100 mm, 1.7 um

#### TUV

- 10mm analytical flow cell
- Sampling rate 10 Hz,  $\lambda$  = 214nm

#### QDa

- SIR acquisition
- 5 Hz sampling rate


# Selected-Ion-Recording (SIR) for PQA/CQA acquisition



THE SCIENCE OF WHAT'S POSSIBLE.

Charge states to be monitored


#### Empower instrument control panel:



#### QDa Function table:

QDa Function table.			Charge states to be monitored				
QDa	Frag	Modification	m/z				
1	1T25	Glycopeptides	FA2-879.2,FA2G1-933.2,FA2G2- 987.3, A2-830.5, M5-803.1, FA1G1- 865.5, FA1G1Gc1-726.2				
2	T1	Pyro-Glu (native)	616.7, 308.9				
3	T21	oxidized	852.0, 426.5				
4	T42	C-term Lysine (native)	788.9, 395.0				
5	T21	native	836.0, 418.5				
6	T1	Pyro-Glu (mod)	599.7, 300.4				
7	T42	C-term Lysine clip	660.7, 330.9				
8	T41	oxidized	705.5, 564.6				
9	T41	Native	836.0, 418.5				
11	T37	PENNYK (deamidated)	849.6, 637.4				
12	T37	PENNYK (Native)	849.2, 637.2				
13	T26	Deamidated	905.5, 604.0				
14	T26	Native	905.1, 603.7				
15	T15	Deamidated	1120.6, 960.6, 840.7, 747.4, 672.7				
16	T15	Native	1120.4, 960.5, 840.6, 747.3, 672.6				









THE SCIENCE OF WHAT'S POSSIBLE.

POSTER Th583 Bridging the analytical workflows for characterizing and monitoring product quality attributes (PQAs) of biotherapeutics by a common data acquisition mode

### Relative quantitation (Mod%) using MS<sup>E</sup> across labs

	Sites		Lab1		Lab2	
Modification			Mod% (Mean)	RSD%	Mod% (Mean)	RSD%
5	HC: DTLM(255)ISR		2.00	3.6	3.58	4.7
Oxidation	HC: DM(125)IFNFYFDVWGQGTTVTVSSASTK		2.24	3.0	5.63	3.8
•	LC: DIQM(4)TQSPSTLSASVGDR		0.90	2.28	1.39	3.3
5	HC: FNWYVDGVEVHN(290)AK		0.17	1.3	0.19	2.9
Deamidation	HC: GFYPSDIAVEWESNGQPEN(392)NYK		3.35	3.6	3.08	3.11
a a	HC: N(364)QVSLTCLVK		1.32	0.61	0.92	1.14
		Aglycosylated	0.65	1.64	0.67	0.72
Ē	EEQYN(300)STYR	G0F	42.05	2.28	39.26	0.45
Glycosylation		G1F	46.46	2.29	48.18	0.25
Glyc		G2F	9.95	0.94	11.02	0.70
		Man5	0.89	0.11	0.87	0.53

#### Comparable performance of MS and MS<sup>E</sup> Data Acquisition

	Sites	Modification%			
Modification		MS only		MSE	
		Control	Degraded	Control	Degraded
5	HC: DTLM(255)ISR	1.36	5.14	1.27	4.87
Oxidation	HC: WQQGNVFSCSVM(431)HEALHNHYTQK	1.19	2.56	0.86	2.45
۰	LC: DIQM(4)TQSPSTLSASVGDR	0.70	1.04	0.72	1.01
	HC: WQQGN(424)VFSCSVMHEALHN(437)HYTQK	0.13	1.11	0.04	1.05
=		0.08	0.17	0.03	0.25
Deamidation	HC: GFYPSDIAVEWESN(387)GQPEN(392)N(393)YK	2.59	12.82	2.59	12.75
eami		2.16	32.36	2.19	32.08
٥	HC: N(364)QVSLTCLVK	0.15	1.12	0.15	1.12
		0.80	0.81	0.90	0.86

# Harmonizing Workflows: UNIFI acquired biopharm data can be analyzed using the most common industry software tools



















# Harmonizing Workflows: UNIFI acquired biopharm data can be analyzed using the most common industry software tools












SimGlycan®








# Now you can access the suite of Protein Metrics capabilities with UNIFI acquired data





- Intact and Subunit Analysis
- PTM Analysis
- HCP Analysis
- Disulfide Bond Analysis
- Sequence Variant Analysis
- MAM Analysis
- Peptide Mapping
- Glycosylation profiling
- Etc...



# WILL YOUR BIOPHARMA DATA LIVE IN CHAOS OR HARMONY?

Visit www.waters.com/tamethechaos to learn more.

(Play Video)

